<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03054402</url>
  </required_header>
  <id_info>
    <org_study_id>18384</org_study_id>
    <secondary_id>2016-002668-15</secondary_id>
    <nct_id>NCT03054402</nct_id>
  </id_info>
  <brief_title>First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845</brief_title>
  <official_title>Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of Increasing Single Oral Doses of BAY1834845 Including Relative Bioavailability of a Liquid Versus a Solid Dosage in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a first in human study that will investigate the safety, tolerability and
      pharmacokinetics and explore the pharmacodynamics of ascending single doses of BAY1834845
      using a placebo controlled, randomized, single center design.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2017</start_date>
  <completion_date type="Actual">March 29, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 25 days after last drug administration</time_frame>
    <description>AEs are considered to be treatment-emergent if they have started or worsened after first application of study medication up to 30 days after end of treatment with study medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of treatment-emergent adverse events</measure>
    <time_frame>Up to 25 days after last drug administration</time_frame>
    <description>The intensity of an AE is classified according to the following categories:
Mild
Moderate
Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration vs. time curve (AUC)</measure>
    <time_frame>Baseline to up to 14 days post drug administration</time_frame>
    <description>AUC from zero to infinity after single dose if possible or from time 0 to the last data point above lower limit of quantification (AUC (0-tlast)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum drug concentration in plasma after single dose administration (Cmax)</measure>
    <time_frame>Baseline to up to 14 days post drug administration</time_frame>
    <description>Maximum drug concentration in plasma in mg/L after single dose administration of BAY1834845</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Pelvic Inflammatory Disease</condition>
  <arm_group>
    <arm_group_label>Dose escalation/BAY1834845</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of BAY1834845 in the morning of the PK profile day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a single dose of placebo in the morning of the PK profile day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1834845</intervention_name>
    <description>Escalating doses of BAY1834845 including comparison of solution and tablet in one dose group</description>
    <arm_group_label>Dose escalation/BAY1834845</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subject

          -  Age: 18 to 50 years (inclusive) at the first screening visit

          -  Body mass index (BMI) : 18.5 ≤ BMI ≤ 30 kg/m²

        Exclusion Criteria:

          -  Clinically relevant findings in the physical examination

          -  Relevant diseases within the last 4 weeks prior to the first study drug administration

          -  Incompletely cured pre-existing diseases for which it can be assumed that the
             absorption, distribution, metabolism, elimination and effects of the study drugs will
             not be normal

          -  Use of systemic or topical medicines or substances which oppose the study objectives
             or which might influence them within 4 weeks before first study drug administration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRS Clinical Research Services Berlin GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2017</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Inflammatory Disease</mesh_term>
    <mesh_term>Pelvic Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

